Laminarin promotes anti-cancer immunity by the maturation of dendritic cells

Oncotarget. 2017 Jun 13;8(24):38554-38567. doi: 10.18632/oncotarget.16170.

Abstract

This research evaluates the effects of laminarin on the maturation of dendritic cells and on the in vivo activation of anti-cancer immunity. In vivo treatment of C56BL/6 mice with laminarin increased the expression levels of co-stimulatory molecules and the production of pro-inflammatory cytokines in spleen dendritic cells. Laminarin enhanced ovalbumin antigen presentation in spleen dendritic cells and promoted the proliferation of OT-I and OT-II T cells. Laminarin also induced the maturation of dendritic cells in tumor-draining lymph nodes and protected interferon-γ and tumor necrosis factor-α and proliferation of OT-I and OT-II T cells in tumors. The combination treatment of laminarin and ovalbumin inhibited B16-ovallbumin melanoma tumor growth and its liver metastasis by antigen-specific immune activation, including cytotoxic T lymphocyte activation and interferon-γ production. Thus, these data demonstrated the potential of laminarin as a new and useful immune stimulatory molecule for use in cancer immunotherapy.

Keywords: adjuvant; anti-cancer; cytotoxic lymphocyte activation; dendritic cell maturation; laminarin.

MeSH terms

  • Animals
  • Antigen Presentation / drug effects
  • Cell Proliferation / drug effects
  • Dendritic Cells / drug effects*
  • Dendritic Cells / immunology
  • Glucans / pharmacology*
  • Immunotherapy / methods*
  • Lymphocyte Activation / drug effects
  • Melanoma, Experimental / immunology*
  • Melanoma, Experimental / pathology
  • Mice
  • Mice, Inbred C57BL

Substances

  • Glucans
  • laminaran